Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•06/08/2026•07:00 ET
0
Whiz Insights
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions
Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8
Get started
Create a free account to read the full story.